All In Biotech

Drug Trial Radar · NCT05840016

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

532

Actual

Start

Aug 17, 2023

Primary completion

Feb 28, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.

Conditions

  • Advanced Squamous Non Small Cell Lung Cancer

Interventions

  • AK112, Carboplatin, PaxlitaxelDrug

    IV infusion,Specified dose on specified days

  • Tislelizumab, Carboplatin, PaxlitaxelDrug

    IV infusion,Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by IRRC per RECIST v1.1Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.